MET and melanoma: Melanoma inhibitory activity (MIA), S100 calcium binding protein B (S-100B), osteopontin (OPN), tissue polypeptide-specific antigen cytokeratin 18 (TSP), macrophage inhibitory cytokine-1 (MIC-1), parkinson protein (DJ-1/PARK7), and soluble hepatocyte growth factor receptor (c-Met) were significantly elevated in serum of metastatic UM patients when compared with nonmetastatic patients [9, 14–25].